Study of independent diagnostic efficacy and co-diagnostic strategies of molecular markers for diabetic cardiomyopathy

Study of independent diagnostic efficacy and co-diagnostic strategies of molecular markers for diabetic cardiomyopathy

Word count of the full article: 4834Diabetic cardiomyopathy (DCM) is defined as myocardial dysfunction in diabetes mellitus (DM) patients independent of coronary artery disease (CAD) or hypertension (HTN). With high morbidity and mortality, DCM poses a significant threat to patient health. Its under...

Full description

Saved in:
Bibliographic Details
Main Authors: Na Su, Jingxuan Zhao, Weiyi Zhang, Xinhuan Zhang, Kunna Lu, Yan Ma, Yan Wang, Mingfeng Cao
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-08-01
Series:Frontiers in Endocrinology
Subjects:
diabetic cardiomyopathy
molecular markers
oxidative stress
non-coding RNA
early diagnosis
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2025.1618230/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Word count of the full article: 4834Diabetic cardiomyopathy (DCM) is defined as myocardial dysfunction in diabetes mellitus (DM) patients independent of coronary artery disease (CAD) or hypertension (HTN). With high morbidity and mortality, DCM poses a significant threat to patient health. Its underlying pathogenesis remains incompletely elucidated, and the prolonged subclinical phase renders early diagnosis and precise treatment clinically challenging. Thus, identifying viable biomarkers for early diagnosis and intervention has emerged as a research imperative, whereas a systematic DCM diagnostic and therapeutic strategy remains to be established. Our examination revealed that circulating soluble suppression of tumorigenicity 2 (sST2), Cardiotrophin-1 (CT-1), and galectin-3 levels correlate closely with DCM progression stages. Combining Lysyl Oxidase-Like 2 (LOXL2) and Electron Transfer Flavoprotein β Subunit (ETFβ) measurements with ultrasound E/E’ ratio and NT-proBNP enhances diagnostic accuracy. Novel noninvasive markers (e.g., skin autofluorescence) show promise. This article comprehensively evaluates the clinical applications of these molecular markers within DCM’s pathophysiological classification framework.
ISSN:1664-2392

Similar Items